Recent Quotes
My Watchlist
Indicators
Cabling Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AnaptysBio, Inc. - Common Stock (NQ:ANAB)

56.20 -0.83 (-1.45%)
Streaming Delayed Price Updated: 12:43 PM EDT, Sep 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AnaptysBio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
AnaptysBio (NASDAQ:ANAB): High Growth Momentum Aligns With a Breakout Setup ↗
Via Chartmill
News headline image
A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next
From Energy Metal News
Via GlobeNewswire
News headline image
Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference
From AnaptysBio, Inc.
Via GlobeNewswire
AnaptysBio (NASDAQ:ANAB) Passes Minervini Trend Template and High Growth Momentum Screen ↗
Via Chartmill
ANAPTYBIO INC (NASDAQ:ANAB) Offers High-Growth Momentum and a Bullish Technical Setup ↗
Via Chartmill
ANAPTYSBIO INC (NASDAQ:ANAB) Shows Minervini Trend Template and High-Growth Momentum Alignment ↗
Via Chartmill
ANAB Stock Falls After It Sues GSK Unit Tesaro Again, Claims Fresh Breach Of 2014 Deal ↗
The dispute centers around Tesaro’s participation in PD-1 trials. 
Via Stocktwits
Topics Lawsuit
News headline image
Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro’s Anticipatory Breach Claim
From AnaptysBio, Inc.
Via GlobeNewswire
Top movers analysis one hour before the close of the markets on 2026-04-20: top gainers and losers in today's session. ↗
Via Chartmill
What's going on in today's session ↗
Via Chartmill
These stocks are gapping in today's session ↗
Via Chartmill
News headline image
Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations
From AnaptysBio, Inc.
Via GlobeNewswire
Top movers in Monday's pre-market session ↗
Via Chartmill
News headline image
Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Announces Participation at Upcoming Investor Conferences
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
What This Insider Trim at AnaptysBio Means for Investors After a 260% Stock Rally ↗
This biotech innovator in antibody therapies just reported a significant insider sale amid a period of strong share price gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
What Investors Should Know About a $163K AnaptysBio Insider Sale ↗
This clinical-stage biotech specializing in antibody therapeutics reported a notable insider sale amid ongoing development and partnerships. 
Via The Motley Fool
Topics Intellectual Property Regulatory Compliance
News headline image
Anaptys Files Motion to Dismiss Tesaro’s Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys to Present at the 44th Annual J.P. Morgan Healthcare Conference
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
AnaptysBio Inc (NASDAQ:ANAB) Meets Minervini Trend Template with High-Growth Momentum ↗
AnaptysBio (ANAB) meets the Minervini Trend Template, showing a powerful technical uptrend backed by accelerating earnings and revenue growth momentum. 
Via Chartmill
News headline image
Anaptys Announces Participation in December Investor Conferences
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
AnaptysBio Inc (NASDAQ:ANAB) Screens as a High-Growth Momentum Leader ↗
AnaptysBio (ANAB) is a high-growth biotech stock with a strong technical uptrend, surging revenue, and impressive relative strength. 
Via Chartmill
News headline image
Anaptys Announces $100 Million Stock Repurchase Plan
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
ANAPTYSBIO INC (NASDAQ:ANAB) Shows High-Growth Momentum and Positive Technical Setup ↗
ANAB stock shows explosive revenue growth and strong technical setup, making it a top momentum pick for biotech investors. 
Via Chartmill
News headline image
AnaptysBio To Save $10 Million After Discontinuing Ulcerative Colitis Study ↗
AnaptysBio ends its ulcerative colitis trial after rosnilimab misses key goals, focusing resources on rheumatoid arthritis and future programs. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
>